HK Stock Market Move | GENFLEET-B(02595) rose more than 22% during the trading day. Recently, GFH375 has been recognized as a breakthrough therapy for the treatment of pancreatic cancer.

GENFLEET-B(02595) rose more than 22% during trading, and as of the time of writing, it was up 14.37% to 44.88 Hong Kong dollars, with a trading volume of 194 million Hong Kong dollars. On the news front, Jin Fang Pharmaceutical recently announced that its orally administered highly selective KRAS G12D (ON/OFF) inhibitor GFH375, developed independently, has been included in the Breakthrough Therapy Designation (BTD) list by the National Medical Products Administration Drug Evaluation Center (CDE), intended for single-agent treatment of KRAS G12D-mutant metastatic pancreatic cancer patients who have received at least one systemic therapy. This is the first domestically recognized single-agent treatment plan for KRAS G12D inhibitors with BTD designation for pancreatic cancer. The company's Chief Medical Officer, Wang Yu, stated that GFH375 has shown excellent efficacy in the treatment of various solid tumors, and they look forward to the smooth progress of its various trials, providing patients with new treatment options. The company also plans to release the latest data on GFH375 in different indications trials at academic conferences later this year. The survival rate of pancreatic cancer is less than 10%, with KRAS mutations occurring in up to 90% of pancreatic cancer cases. The company's participation in the project "Research on the Mechanism of Pancreatic Cancer Occurrence and Clinical Precision Diagnosis and Treatment New Paradigm" has been recognized as a national key R&D project in 2025.